stockrow
Friday 6 November 2026
Export TRLV’s income statement to Excel — free account
Trulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
11.07
0.53
−4.57%
Follow TRLV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.95 | 1.66 | 0.92 | 1.41 | |
P/FCF ratio |
11.66 | 10.39 | 4.90 | 7.98 | |
P/Operating CF |
28.26 | 35.65 | 19.36 | 28.08 | |
P/B ratio |
2.73 | 2.47 | 0.94 | 1.45 | |
Price to Tangible BV |
13.90 | 13.55 | 0.00 | 0.00 | |
EV/Sales |
1.96 | 1.68 | 0.93 | 1.44 | |
EV/EBITDA |
0.00 | 0.00 | 3.42 | 5.36 | |
EV/Operating CF |
8.75 | 7.83 | 3.91 | 6.23 | |
EV/FCF |
11.77 | 10.50 | 4.93 | 8.15 | |
Quick Ratio |
0.00 | 3.71 | 3.01 | 2.16 | |
Current Ratio |
5.52 | 5.94 | 5.26 | 4.43 | |
Net Debt/EBITDA |
— | (0.06) | 0.09 | 0.61 | |
Debt/Assets |
0.00% | 16.61% | 12.95% | 10.82% | |
Debt/Equity |
0.00 | 0.45 | 0.31 | 0.26 | |
Asset Turnover |
0.43 | 0.46 | 0.41 | 0.42 | |
Operating CF/Net income |
85.64 | (0.13) | 23.15 | (1.38) | |
Capex/Depreciation |
— | (0.54) | (0.31) | (0.16) | |
Interest Coverage |
0.00 | (28.73) | 2.66 | 1.07 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
38.16% | 37.56% | 36.58% | 43.09% | |
Intangible Assets out of Total Assets |
0.29 | 0.30 | 0.45 | 0.48 | |
Share Based Compensation of Revenue |
2.56% | 2.55% | 1.44% | 1.36% | |
Graham Net Nets |
(0.37) | (0.39) | (0.91) | (0.60) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(22.63%) | (25.09%) | (8.04%) | (7.16%) | |
Free Cash Flow Yield |
8.57% | 9.62% | 20.42% | 12.53% | |
Revenue per Share |
1.19 | 1.41 | 1.49 | 1.53 | |
Operating CF per Share |
0.39 | 0.28 | 0.29 | 0.31 | |
Capex per Share |
0.00 | (0.11) | (0.07) | (0.04) | |
Free Cash Flow per Share |
0.39 | 0.17 | 0.22 | 0.27 | |
Cash per Share |
0.00 | 1.69 | 1.83 | 1.34 | |
Shareholders Equity per Share |
4.00 | 3.97 | 5.97 | 5.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.00 | 3.97 | 5.97 | 5.97 | |
Free Cash Flow |
74.42 | 32.13 | 42.22 | 52.11 | |
Working Capital |
460.81 | 469.77 | 528.80 | 435.77 | |
Capital Expenditures |
— | (21.01) | (13.48) | (7.10) | |
Net Current Asset Value |
(783.92) | (746.69) | (979.66) | (990.37) | |
EV/EBIT |
0.00 | 0.00 | 7.55 | 11.84 | |
Capex to Sales |
0.00 | 0.08 | 0.05 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 7.50 | 11.59 | |
| Other line items | |||||
Average Receivables |
— | 22.55 | 19.85 | 18.63 | |
Average Payables |
74.74 | 70.27 | 85.04 | 88.35 | |
Average Inventory |
217.06 | 214.17 | 240.80 | 236.83 | |
Average Assets |
2,529.93 | 2,499.64 | 2,834.79 | 2,783.18 | |
Average Common Equity |
978.91 | 987.69 | 1,184.10 | 1,196.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026